NTRK1 is altered in 2.96% of malignant solid tumor patients with NTRK1 Amplification present in 0.47% of all malignant solid tumor patients [4].

NTRK1 Amplification is an inclusion criterion in 9 clinical trials for malignant solid tumor, of which 7 are open and 2 are closed. Of the trials that contain NTRK1 Amplification and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

NTRK1 is altered in 7.67% of melanoma patients with NTRK1 Amplification present in 0.87% of all melanoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.42% of breast carcinoma patients with NTRK1 Amplification present in 0.61% of all breast carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.4% of ovarian carcinoma patients with NTRK1 Amplification present in 0.56% of all ovarian carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 3.88% of non-small cell lung carcinoma patients with NTRK1 Amplification present in 0.51% of all non-small cell lung carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 1.83% of pancreatic carcinoma patients with NTRK1 Amplification present in 0.44% of all pancreatic carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 1.27% of lymphoma patients with NTRK1 Amplification present in 0.26% of all lymphoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain NTRK1 Amplification and lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

NTRK1 is altered in 3.06% of head and neck squamous cell carcinoma patients with NTRK1 Amplification present in 0.1% of all head and neck squamous cell carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

NTRK1 is altered in 1.26% of cervical carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NTRK1 is altered in 4.49% of hepatocellular carcinoma patients with NTRK1 Amplification present in 2.69% of all hepatocellular carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 4.94% of thymoma patients with NTRK1 Amplification present in 2.63% of all thymoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for thymoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and thymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 4.0% of desmoplastic small round cell tumor patients with NTRK1 Amplification present in 1.39% of all desmoplastic small round cell tumor patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NTRK1 is altered in 2.17% of soft tissue sarcoma patients with NTRK1 Amplification present in 1.24% of all soft tissue sarcoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 4.26% of malignant uterine neoplasm patients with NTRK1 Amplification present in 1.17% of all malignant uterine neoplasm patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.34% of bile duct carcinoma patients with NTRK1 Amplification present in 1.09% of all bile duct carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 1.33% of adenoid cystic carcinoma patients with NTRK1 Amplification present in 0.79% of all adenoid cystic carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 3.89% of lung carcinoma patients with NTRK1 Amplification present in 0.51% of all lung carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 4.44% of gallbladder carcinoma patients with NTRK1 Amplification present in 0.43% of all gallbladder carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.42% of head and neck carcinoma patients with NTRK1 Amplification present in 0.32% of all head and neck carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.26% of bladder carcinoma patients with NTRK1 Amplification present in 0.27% of all bladder carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 1.45% of non-hodgkin lymphoma patients with NTRK1 Amplification present in 0.27% of all non-hodgkin lymphoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 2.28% of gastric adenocarcinoma patients with NTRK1 Amplification present in 0.13% of all gastric adenocarcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 0.74% of hematopoietic and lymphoid malignancy patients with NTRK1 Amplification present in 0.12% of all hematopoietic and lymphoid malignancy patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 2.32% of esophagogastric carcinoma patients with NTRK1 Amplification present in 0.05% of all esophagogastric carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for esophagogastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and esophagogastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 3.35% of colorectal carcinoma patients with NTRK1 Amplification present in 0.03% of all colorectal carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 1.49% of prostate carcinoma patients with NTRK1 Amplification present in 0.03% of all prostate carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 0.52% of acute myeloid leukemia patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 1.89% of adenocarcinoma of the gastroesophageal junction patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 2.86% of anaplastic large cell lymphoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 4.27% of esophageal squamous cell carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NTRK1 is altered in 0.86% of mesothelioma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 is altered in 3.7% of squamous cell lung carcinoma patients [4].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NTRK1 Amplification is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 Amplification and thymic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].